logo

BBNX

Beta Bionics·NASDAQ
--
--(--)
--
--(--)
1.89 / 10
Underperform

The security demonstrates inadequate fundamental health (1.9/10). Positive indicators: Net profit attributable to parent company shareholders / Net profit (%) and Cash-UP, but headwinds are noted in Net income-Revenue and Cash-MV. Analytical conclusion: challenging.

Fundamental(1.89)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-1.51
Score2/3
Weight-0.47%
1M Return0.09%
ROA (%)
Value-24.91
Score2/3
Weight2.10%
1M Return-0.39%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight9.10%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight12.85%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight22.19%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-33.21
Score2/3
Weight2.10%
1M Return-0.39%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight10.26%
1M Return-1.95%
Asset-MV
Value-0.50
Score1/3
Weight3.58%
1M Return-0.63%
Cash-MV
Value-0.07
Score1/3
Weight24.38%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight13.92%
1M Return-2.89%
Is BBNX fundamentally strong?
  • BBNX scores 1.89/10 on fundamentals and holds a Premium valuation at present. Backed by its -32.22% ROE, -87.89% net margin, -7.40 P/E ratio, 1.95 P/B ratio, and 53.65% earnings growth, these metrics solidify its Underperform investment rating.